中国银河给予迪哲医药推荐评级，迪哲医药2025年中报业绩点评：核心产品增长强劲，创新管线数据亮眼

Group 1 - The core viewpoint of the article is that China Galaxy has given a recommendation rating to Dize Pharmaceutical (688192.SH) based on significant clinical benefits from its products and advancements in its innovation pipeline [1] Group 2 - The FDA approval of Shuwotini and the notable clinical benefits of Golixitin are highlighted as key reasons for the positive rating [1] - The innovation pipeline is progressing smoothly, with impressive data from dual-target BTK and fourth-generation EGFRTKI [1]